Close Menu

Beckman Coulter

Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.

The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.

The FDA said Beckman Coulter notified customers on Monday of an updated urgent medical device recall letter that replaces an initial notification last year.

The company formally debuted the DxA 5000 at EuroMedLab 2019 this week as management pointed to its importance in the rejuvenation to the firm's pipeline.

A Roche executive said he expects essentially all the firm's US troponin customers will convert to the high-sensitivity assay over the next two to three years.

GenMark Diagnostics received clearance for a third BCID panel that the firm said paves the way for a customizable approach to sepsis MDx.

The company said that the DxA 5000 reduces the number of required manual steps and can shorten the preanalytical processing time by up to 73 percent.

The firm said that the test, a hematology-based cellular biomarker that identifies morphological changes within monocyte white blood cells, could speed diagnosis.

A display at a booth at ECCMID where antimicrobial resistance was a major theme.

Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.

The firm said that its new hematology-based cellular biomarker test has the potential to advance clinicians’ approach to sepsis triage and diagnosis.

Pages